Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of DSIP and FOXO4-DRI — mechanism, dosing, side effects, legal status, and pricing.
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 by Schoenenberger and Monnier from cerebral venous blood of rabbits during electrically induced sleep. It has been studied as a putative sleep and stress modulator, but the evidence base is weak, largely pre-2000, and DSIP is not FDA-approved.
DSIP
FOXO4-DRI
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
DSIP
FOXO4-DRI
COA corpus from Disclosed Labs — independently tested batches only.
DSIP
69
COAs
99.4%
Avg purity
14
Labs
FOXO4-DRI
5
COAs
99.5%
Avg purity
4
Labs
DSIP is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. FOXO4-DRI remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Schoenenberger & Monnier first isolated and characterized DSIP in 1977 (PNAS 74(3):1282-6, PMID 265572). Graf & Kastin's 1984 review (Neurosci Biobehav Rev, PMID 6145137) summarized the first decade of work, noting reported effects on sleep, pain, and stress but also substantial inconsistency across labs and species. Schneider-Helmert (Eur Neurol 1986, PMID 3792404) reported sleep normalization in 18 middle-aged and elderly chronic insomniacs given DSIP over one week — small, open, and never replicated at scale. Schneider-Helmert et al. (Dtsch Med Wochenschr 1987, PMID 3582201) explored phase-shifted insomnia. Kovalzon & Strekalova (J Neurochem 2006, PMID 16539679) summarized the field as a 'still unresolved riddle,' noting that no DSIP receptor or gene has been identified. No Phase 3 trials, no FDA approval, no modern controlled replication.
Key references
Baar et al. (Cell, 2017, PMID 28340339) identified FOXO4 as a pivot for senescent-cell viability and designed a cell-penetrating D-retro-inverso peptide that disrupts the FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells while sparing proliferating cells. In vivo, the peptide neutralized doxorubicin chemotoxicity and, in fast-aging XpdTTD/TTD and naturally aged mice, restored fur density, renal function, and fitness. This is the only primary in vivo study; evidence is preclinical only. No human clinical trials have been registered or completed. Safety in humans is unknown — as a systemic senolytic inducing apoptosis, theoretical risks include impaired wound healing, immune perturbation, and off-target effects on quiescent stem-cell populations.
Key references
DSIP (Cognitive) and FOXO4-DRI (Metabolic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs